Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Women’s health

Pregnant women at risk of mental health problems need more support, says NICE

Guideline includes a raft of recommendations about medicines management and drug choices.

Women with a history of mental health problems should receive additional support before, during and after their pregnancy, according to guidance issued by the National Institute for Health and Care Excellence (NICE)

Source: Nic Cleave / Alamy

Prescribers need to work with patients to consider the individual woman’s best interests

A woman with a history of mental health problems should receive additional support before, during and after her pregnancy, according to guidance issued by the National Institute for Health and Care Excellence (NICE)[1].

The updated national guidelines for the clinical management of antenatal and postnatal mental health are designed to help prescribers “contextualise” their decisions, according to Louise Howard, professor of women’s health at King’s College London and chairwoman of the group that developed them.

“The context of the decision is everything – the need to work with the patient and to consider the individual woman’s best interests,” she says. “On balance, when one is thinking about the risks and balances, the right approach for her might be to continue the medication.”

The NICE guideline, which replaces the advice published in 2007, includes a raft of recommendations about medicines management and drug choices.

In a change to the 2007 guideline, NICE now says that valproate should never be prescribed to treat acute or long-term mental health problems in women of childbearing age since alternatives are available.

NICE also warns prescribers to take into account the reproductive safety of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) or serotonin-noradrenaline reuptake inhibitors (SNRIs) prescribed during pregnancy and the uncertainty about whether there is any increased risk to the foetus.

Prescribers should choose a drug that poses the least risk, and use the lowest possible dose.

New specific drug recommendations include the need to check lamotrigine levels frequently – including during postnatal care – because the levels “vary substantially” at these times.

Lithium should not be offered to women who are planning a pregnancy or who are pregnant, unless antipsychotic medication has not been effective, according to the guideline. If lithium is offered then the potential risks to the foetus should be made clear to the woman, it says.

Howard believes the accompanying advice for patients will help women ask the right questions about their mental health management.

“The issue for patients is what works best for them as an individual,” she says. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067460

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and British National Formulary for Children

    BNF and British National Formulary for Children

    Now available as a 1 year print subscription to both the BNF and British National Formulary for Children, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and British National Formulary for Children

    BNF and British National Formulary for Children

    Now available as a 2 year print subscription to both the BNF and British National Formulary for Children, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.